About
Technology
Issues
FAQ
Links
Official Page
Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial
Distribution of the number of citations over years.
site/software ©
exaly
; All materials licenced under
CC by-SA
.